Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis
- 11 June 2004
- journal article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 20 (8), 1269-1273
- https://doi.org/10.1185/030079904125004385
Abstract
SUMMARYObjectives: The effects of tacrolimus, a new immunosuppressive drug, which inhibits calcineurin pathway and also might enhance corticosteroid (CS) receptor-mediated gene expressions, on clinical outcome and biochemical data were evaluated in thymectomised and steroid-dependent myasthenia gravis (MG) patients.Patients and Methods: We administrated low-dose tacrolimus (3 mg/day orally) to 17 steroid-dependent thymectomised mg patients. They were followed for 4 to 58 months, average 19.2 months. The mg activities of daily living (MGADL) scores and the dosage of prednisolone (PSL) were assessed at baseline and 4 months later.Results: The average MGADL scores improved from 6.8 to 5.0 ( p < 0.01) at 4 months; to 3.5 at the last visit ( p < 0.01) as well as the average dosage of PSL reducing from 31.6 to 24.1 mg/alternate day ( p < 0.01) at 4 months; 14.6 mg at the last visit ( p < 0.01).Conclusions: The additional low dose tacrolimus therapy for steroid-dependent thymectomised mg is effective in improvin...This publication has 11 references indexed in Scilit:
- Effects of FK506 on myasthenia gravis patients with high interleukin‐2 productivity in peripheral blood mononuclear cellsMuscle & Nerve, 2002
- New therapies in systemic lupus erythematosusBest Practice & Research Clinical Rheumatology, 2002
- Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese diabetic miceDiabetologia, 2002
- Successful treatment of myasthenia gravis with tacrolimusMuscle & Nerve, 2001
- Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review) [RETIRED]Neurology, 2000
- Myasthenia gravis activities of daily living profileNeurology, 1999
- Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three casesAnnals Of The Rheumatic Diseases, 1997
- CYCLOSPORINE, FK-506, RAPAMYCIN, AND OTHER IMMUNOMODULATORSRheumatic Disease Clinics of North America, 1996
- Cyclosporin A potentiates the dexamethasone-induced mouse mammary tumor virus-chloramphenicol acetyltransferase activity in LMCAT cells: a possible role for different heat shock protein-binding immunophilins in glucocorticosteroid receptor-mediated gene expression.Proceedings of the National Academy of Sciences of the United States of America, 1995
- Cyclosporin A, FK-506, and Rapamycin: Pharmacologic Probes of Lymphocyte Signal TransductionAnnual Review of Immunology, 1992